Literature DB >> 10326360

Outcomes of 4 methods of debridement using a decision analysis methodology.

B A Mosher1, J Cuddigan, D R Thomas, D M Boudreau.   

Abstract

OBJECTIVE: To compare the clinical efficacy of 4 debridement alternatives in pressure ulcer management.
DESIGN: Nonexperimental design combining computer modeling and a decision analysis methodology. Data input into the model were derived from a literature review of the MEDLINE database for the years 1985 to 1995 (indexing terms: pressure ulcer, decubitus, economics, cost-effectiveness, and outcome) and a Delphi consensus process with an independent panel of 9 specialists in geriatric care.
SETTING: Long-term care. PATIENTS: Hypothetical elderly female resident with a new full-thickness pressure ulcer (mild odor, minimal draining, no undermining, intact periulcer skin).
INTERVENTIONS: The study patient underwent 1 month of therapy with each of 4 debridement methods: autolysis, wet-to-dry dressings, collagenase (Santyl) or fibrinolysin (Elase). MAIN OUTCOME: Specific clinical outcomes (time to clean wound bed, risk of infection) and relative cost-effectiveness of each debridement method were calculated.
RESULTS: The likelihood of achieving a clean wound bed at 2 weeks was 70% for collagenase, 57% for fibrinolysin, 50% for autolysis, and 30% for wet-to-dry dressings. The total cost for 1 month of treatment was $610.96 for collagenase, $920.73 for autolysis, $986.38 for fibrinolysin, and $1,008.72 for wet-to-dry dressings.
CONCLUSIONS: The study patient was most likely to have a clean wound bed after 2 and 4 weeks of treatment, less likely to need to switch debridement methods, and of equal or less likelihood of experiencing and infection and subsequent hospitalization when her wound was debrided with collagenase. Treatment with collagenase also resulted in the lowest total cost of treatment. Longer term, prospective studies using actual utilization data are needed to refine these estimates of the clinical and cost-effectiveness of each product.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326360

Source DB:  PubMed          Journal:  Adv Wound Care        ISSN: 1076-2191            Impact factor:   4.730


  6 in total

1.  The cost of wound debridement: a Canadian perspective.

Authors:  Kevin Y Woo; David Keast; Nancy Parsons; R Gary Sibbald; Nicole Mittmann
Journal:  Int Wound J       Date:  2013-07-09       Impact factor: 3.315

2.  Collagenase for Wound Debridement in the Neonatal Intensive Care Unit: A Retrospective Case Series.

Authors:  Elizabeth Huett; Whitney Bartley; Darla Morris; Della Reasbeck; Beth McKitrick-Bandy; Charlotte Yates
Journal:  Pediatr Dermatol       Date:  2017-05       Impact factor: 1.588

3.  Collagenase promotes the cellular responses to injury and wound healing in vivo.

Authors:  Kathleen N Riley; Ira M Herman
Journal:  J Burns Wounds       Date:  2005-05-17

4.  Pressure ulcers: Current understanding and newer modalities of treatment.

Authors:  Surajit Bhattacharya; R K Mishra
Journal:  Indian J Plast Surg       Date:  2015 Jan-Apr

5.  Comparative Effectiveness of Clostridial Collagenase Ointment to Medicinal Honey for Treatment of Pressure Ulcers.

Authors:  Adrienne M Gilligan; Curtis R Waycaster; Richard Bizier; Bong-Chul Chu; Marissa J Carter; Caroline E Fife
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-04-01       Impact factor: 4.730

6.  Novel mechanisms of Collagenase Santyl Ointment (CSO) in wound macrophage polarization and resolution of wound inflammation.

Authors:  Amitava Das; Soma Datta; Eric Roche; Scott Chaffee; Elizabeth Jose; Lei Shi; Komel Grover; Savita Khanna; Chandan K Sen; Sashwati Roy
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.